Randomized phase III trial of erlotinib versus docetaxel as second-or third-line therapy in patients with advanced non–small-cell lung cancer: Docetaxel and Erlotinib …
T Kawaguchi, M Ando, K Asami, Y Okano… - Journal of clinical …, 2014 - ascopubs.org
Purpose To investigate the efficacy of erlotinib versus docetaxel in previously treated
patients with advanced non–small-cell lung cancer (NSCLC) in an epidermal growth factor …
patients with advanced non–small-cell lung cancer (NSCLC) in an epidermal growth factor …
TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non–small-cell lung cancer
RS Herbst, D Prager, R Hermann… - Journal of clinical …, 2005 - ascopubs.org
Purpose Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …
tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised …
MC Garassino, O Martelli, M Broggini, G Farina… - The lancet …, 2013 - thelancet.com
Background Erlotinib is registered for treatment of all patients with advanced non-small-cell
lung cancer (NSCLC). However, its efficacy for treatment of patients whose tumours are …
lung cancer (NSCLC). However, its efficacy for treatment of patients whose tumours are …
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non–small-cell lung cancer
Purpose This study investigated whether sequential administration of erlotinib and
chemotherapy improves clinical outcomes versus chemotherapy alone in unselected …
chemotherapy improves clinical outcomes versus chemotherapy alone in unselected …
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non–small-cell lung cancer and a performance status of 2
R Lilenbaum, R Axelrod, S Thomas… - Journal of Clinical …, 2008 - ascopubs.org
Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …
first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a …
Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non–small-cell lung cancer who progressed on prior chemotherapy
SE Witta, RM Jotte, K Konduri, MA Neubauer… - Journal of clinical …, 2012 - ascopubs.org
Purpose Histone deacetylase inhibitors (HDACis) have been shown to overcome resistance
to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) linked to …
to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) linked to …
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non–small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial
U Gatzemeier, A Pluzanska, A Szczesna… - Journal of Clinical …, 2007 - ascopubs.org
Purpose Erlotinib is a potent inhibitor of the epidermal growth factor receptor tyrosine kinase,
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …
with single-agent antitumor activity. Preclinically, erlotinib enhanced the cytotoxicity of …
TRIBUTE-A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC)
RS Herbst, D Prager, R Hermann, V Miller… - Journal of Clinical …, 2004 - ascopubs.org
7011 Background: Tarceva™(erlotinib) is a potent reversible HER1/EGFR tyrosine kinase
inhibitor with single-agent antitumor activity. TRIBUTE was a prospective, placebo-controlled …
inhibitor with single-agent antitumor activity. TRIBUTE was a prospective, placebo-controlled …
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
U Gatzemeier, A Pluzanska, A Szczesna… - Journal of Clinical …, 2004 - ascopubs.org
7010 Background: Oral erlotinib is a potent HER1/EGFR tyrosine kinase-phosphorylation
inhibitor with single-agent antitumor activity and has shown additive effects when added to …
inhibitor with single-agent antitumor activity and has shown additive effects when added to …
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non–small-cell lung cancer: the TORCH randomized trial
C Gridelli, F Ciardiello, C Gallo, R Feld… - Journal of Clinical …, 2012 - ascopubs.org
Purpose Erlotinib prolonged survival of unselected patients with advanced non–small-cell
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …
相关搜索
- lung cancer trial of erlotinib
- small cell lung cancer
- lung cancer randomized phase
- lung cancer therapy in patients
- phase iii trial of erlotinib
- lung cancer performance status
- lung cancer erlotinib hydrochloride
- lung cancer erlotinib in combination
- lung cancer sequential erlotinib
- lung cancer entinostat in patients
- lung cancer paclitaxel chemotherapy
- lung cancer prior chemotherapy
- lung cancer standard chemotherapy
- lung cancer cisplatin and gemcitabine
- erlotinib hcl carboplatin and paclitaxel
- trial of erlotinib randomized phase